Organisation paid for research Program year 2025 Source: CMS Open Payments

Nova Clinical Research, LLC

Neither a doctor nor a teaching hospital

Research payments

$544,406

92 payments

Through program year 2025, Nova Clinical Research, LLC is reported as receiving $544,406 in research payments, across 92 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $59,688 27
2024 Research $154,688 22
2023 Research $23,490 11
2022 Research $245,757 19
2020 Research $31,760 7
2019 Research $29,023 6

Breakdown

Who paid Research payments · program years 2019–2025
  1. Akebia Therapeutics Inc $216,487 11 payments
  2. Shockwave Medical, Inc $94,163 7 payments
  3. Penumbra, Inc. $81,897 16 payments
  4. Bayer HealthCare Pharmaceuticals Inc. $66,693 29 payments
  5. Pacira Pharmaceuticals Incorporated $23,951 18 payments
  6. Gilead Sciences, Inc. $20,760 2 payments
  7. Vifor (International) Ltd. $13,500 4 payments
  8. E.R. Squibb & Sons, L.L.C. $10,570 2 payments
  9. US WorldMeds, LLC $10,500 2 payments
  10. Amarin Pharma Inc. $5,885 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects $206,349 7 payments
  2. Forward PAD $94,163 7 payments
  3. Strike-Pe $81,897 16 payments
  4. BAY94-8862 LCM HFmr/pEF (EF 40%) $49,898 22 payments
  5. A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera®° system in Subjects with Upper Extremity Spasticity $23,951 18 payments
  6. BAY 948862, A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fracti $16,795 7 payments
  7. Diamond Pat-Cr-302 $13,500 4 payments
  8. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Disease $13,000 1 payment
  9. Myobloc Adult LL Spasticity Post-Marketing Commitments $10,500 2 payments
  10. Akb-6548-Ci-0015 $10,138 4 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record